Dr. Hill on the Impact of the COVID-19 Pandemic in MCL


In Partnership With:

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician at Taussig Cancer Institute, as well as an assistant professor of Hematology and Oncology at the Cleveland Clinic, discusses the impact of the coronavirus disease 2019 (COVID-19) pandemic on patients with mantle cell lymphoma (MCL).

 The COVID-19 pandemic has had a profound effect on the treatment of patients with cancer. However, MCL can be a highly proliferative disease. As such, the most effective therapies need to be given, says Hill.

With appropriate precautions, such as wearing masks and social distancing, patients are able to receive traditional chemotherapy regimens during the COVID-19 era, Hill explains.

Furthermore, the risk of contracting COVID-19 is minimal for patients compared with the risk of not receiving optimal therapy, Hill explains. 

For these reasons, COVID-19 has not had as significant of an impact on treatment recommendations in MCL compared with other tumor types, Hill concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine